Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A systems approach to model metastatic progression.

Barry S Taylor1, Sooryanarayana Varambally, Arul M Chinnaiyan

  • 1Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Cancer Research
|June 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>TERT</i> Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract.

European urology open science·2022
Same author

Biochemical characterization of the interaction between KRAS and Argonaute 2.

Biochemistry and biophysics reports·2022
Same author

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.

Nature·2021
Same author

Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need.

Urology·2021
Same author

G3BP1 inhibits Cul3<sup>SPOP</sup> to amplify AR signaling and promote prostate cancer.

Nature communications·2021
Same author

Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.

European urology oncology·2021
Same journal

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

Cancer research·2026
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
See all related articles

Researchers developed a new model using proteomic and transcriptomic data to identify a molecular signature predicting prostate cancer progression and patient prognosis. This signature also showed promise in predicting outcomes for other solid tumors.

Area of Science:

  • Proteomics and genomics
  • Cancer biology
  • Systems biology approaches

Background:

  • High-throughput proteomic platforms offer potential for disease profiling, but data complexity hinders diagnostic breakthroughs.
  • Prostate cancer progression and metastasis remain challenging to predict prognostically.
  • Integrating proteomic and transcriptomic data is crucial for understanding complex diseases.

Purpose of the Study:

  • To develop an integrative model for identifying a molecular signature of metastatic progression in prostate cancer.
  • To assess the predictive capability of this signature for prognosis in prostate cancer and other solid tumors.
  • To highlight the utility of a systems biology approach in deciphering human diseases.

Main Methods:

  • Direct proteomic analysis of tumor tissue extracts.

Related Experiment Videos

  • Differential feature selection to identify proteomic alterations in prostate cancer subclasses.
  • Integration of proteomic data with public and study-derived genomic datasets.
  • Construction of a multiplex gene signature for disease progression.

    • Main Results:

    • An integrative model successfully identified a molecular signature linked to prostate cancer progression from indolent to aggressive disease.
    • The developed gene signature demonstrated efficacy in predicting clinical outcomes across various solid tumors.
    • This approach provides a robust framework for biomarker discovery in cancer.

    Conclusions:

    • An integrative proteomic and transcriptomic systems approach can effectively identify molecular signatures for cancer progression.
    • The identified signature serves as a promising prognostic predictor for prostate cancer and potentially other malignancies.
    • This work underscores the potential of systems biology in advancing cancer diagnostics and prognostics.